Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective faithfully but unsuccessfully to produce an one off therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be being used is an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV happen to be closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of the past few shares of mine. The 1st CytoDyn article of mine, “CytoDyn: What to be able to Do When It is Too Good In order to Be True?”, set out the following prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan presented such a highly marketing picture in the Uptick Newswire job interview that I came away with a poor viewpoint of the company.

Irony of irony, the poor viewpoint of mine of the business has grown steadily, although the disappointment has not been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > six bagger yet still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much storied therapy (which I shall relate to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the treatment as well as reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s payment of $3.5 million transfers ownership of this technology and linked intellectual property coming from Progenics to CytoDyn, as well as roughly twenty five million mg of majority drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 zillion) and the first new drug application endorsement ($5 million), and even royalty payments of five % of net sales upon commercialization.

Since that time, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous indications and numerous therapies, it’s this single therapy and a “broad pipeline of indications” as it puts it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially beneficial therapy of dozens of indications.

Its opening banner on the website of its (below) shows an energetic business with diverse interests albeit centered on leronlimab, several disease sorts, multiple presentations and multiple publications.

Might all of it be smoke and mirrors? That is a question I’ve been asking myself with the really beginning of my interest in this organization. Judging by the multiples of thousands of various comments on listings accessible via Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this particular question.

CytoDyn is a classic battleground, or even some may say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *